4D Molecular Therapeutics announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic Area Head, Pulmonology; Raphael Schiffmann, M.D. has joined as Senior Vice President & Therapeutic Area Head, Cardiology; and Robert Kim, M.D., M.B.A. has joined as Senior Vice President & Clinical Therapeutic Area Head, Ophthalmology. Dr. Robert Fishman has over 20 years of experience in product development including both medicines and aerosol-based drug/device combinations. Dr. Fishman was most recently Chief Medical Officer at Xoc Pharmaceuticals. Previously, he was Senior Vice President, Clinical Development, at InterMune (acquired by Roche), where he led the final pivotal trial of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. Dr. Fishman trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford University pulmonary medicine faculty. Dr. Raphael Schiffmann has over 30 years of experience in clinical research, including as an expert on neurometabolic diseases, focusing his research efforts on lysosomal storage disorders. Dr. Schiffmann’s writings include 275 peer-reviewed publications in scholarly journals, and 19 book chapters and reviews. Prior to joining 4DMT, he was the Director of the Institute of Metabolic Disease at the Baylor Research Institute. Before that, Dr. Schiffmann was the lead investigator in the Developmental and Metabolic Neurology Branch at the National Institute of Neurological Disorders and Stroke (NINDS). Dr. Robert Kim has over 20 years of product development experience in ophthalmology. Prior to joining 4DMT, Robert was Chief Medical Officer at Viewpoint Therapeutics, where he led translational development efforts for a-crystallin pharmacologic chaperones. Prior to Viewpoint, he was Chief Medical Officer at Apellis Pharmaceuticals and Vision Medicines. Earlier in his career, Robert was Vice President and Head of Pharmaceutical Product Development at Novartis/Alcon and Vice President of Clinical Ophthalmology at GSK.
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
4D MOLECULAR THERAPEUTICS, INC. 
